Autonomic Failure Clinical Trial
Official title:
Plasma Exchange for Autoimmune Autonomic Failure
Verified date | April 16, 2009 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will explore whether an antibody is influencing the autonomic nervous system, and
if its removal will eliminate signs and symptoms of failure in that system. The autonomic
nervous system is responsible for many automatic changes involved in everyday activities,
such as standing up, digesting food, and exercising in the heat. Antibodies fight germs but
sometimes cause health problems. Removal of the antibody is done through a procedure called a
plasma exchange.
Patients with primary chronic autonomic failure and a circulating antibody to what is called
the neuronal nicotinic receptor may be eligible for this study. To be eligible, patients will
have participated in an earlier study, protocol number 03-N-0004. Patients will undergo tests
and procedures that include an electrocardiogram, and blood collection for hepatitis, HIV,
and pregnancy. Blood will be tested for a complete blood count, clotting factors, and
chemistries. There will also be tests for liver function, kidney function, cortisol, and
thyroid. Participants will be tested for signs and symptoms of autonomic failure, and will be
asked to complete questionnaires about various symptoms before the plasma exchange, 1 or 2
weeks afterward, and then monthly or bimonthly for up to 1 year. Patients will undergo a
series of other tests. In one test, a patient is upright and blows against a resistance
(Valsalva maneuver). The quantitative sudomotor axon reflex test (QSART) uses iontophoresis,
involving application of acetylcholine, a chemical messenger, and a small amount of
electricity. QSART examines the regulation of sweating, a particular aspect of the autonomic
nervous system. There will be a test using edrophonium, given intravenously (IV), to evaluate
that drug's effects on the heart, skin, glands, gastrointestinal activity, bladder tone, and
salivation. A glucagon test, also by IV, will show patients' ability to release the hormone
adrenaline.
The plasma exchange will be performed by use of an automated cell separator. Patients' blood
will be removed continuously through a needle in the arm. Blood cells will be separated from
the plasma by a spinning process and continuously returned to circulation through a needle in
the patients' opposite arm. Blood cells that are returned will be mixed with albumin, a
sterile replacement solution. A blood thinner, citrate, will be given, to prevent clotting of
blood. This whole procedure will take about 2 hours. Patients will typically undergo five
exchange procedures in about 10 days while they are inpatients at the NIH Clinical Center.
The amount of plasma removed in a single session and the number of sessions will be set by
the NIH Blood Bank. It is expected that patients' autonomic failure will improve after
several days of starting the plasma exchange. Testing for symptoms of autonomic failure and
autonomic function testing will occur about 1 month after the plasma exchange and monthly or
bimonthly for up to 1 year. For each visit of testing, patients will be inpatients for about
2 days. If autonomic failure recurs, patients may have a second plasma exchange, with the
same follow-up tests, for about 1 year.
Status | Completed |
Enrollment | 3 |
Est. completion date | April 16, 2009 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility |
- INCLUSION CRITERIA: The subjects have primary chronic autonomic failure, intact cardiac sympathetic innervation, and a circulating antibody to the nicotinic cholinergic receptor mediating ganglionic neurotransmission. This triad will be identified based on results of participation in NIH Clinical Protocol 03-N-0004. EXCLUSION CRITERIA: Subjects are excluded if they do not meet all three of the above Inclusion Criteria. Venous Access Candidate subjects are excluded if there is inadequate peripheral venous access, identified during participation in NIH Clinical Protocol 03-N-0004. Abnormal Clinical Pathology Test Results Candidate subjects are excluded based on abnormal Clinical Pathology results identified during participation in NIH Clinical Protocol 03-N-0004 (platelet count less than 100,000 per microliter, HIV-1 or 2 or chronic hepatitis B or C infection, or pregnancy). Medical Risk Candidate subjects are excluded for safety reasons if, in the opinion of the Associate Investigator of the NIH Department of Transfusion Medicine (DTM), therapeutic plasma exchange would pose an excessive risk of complications (e.g., stroke, hemorrhage, infection) outweighing the potential scientific and clinical benefit. In female patients with child-bearing potential, a blood test for pregnancy is done prior to testing on each visit. The finding of a positive test for pregnancy excludes the patient from further participation. Patients with autonomic failure have an increased risk of hypotension in response to manipulations that decrease venous return to the heart, such as plasma exchanges. Patients with autonomic failure typically also have high blood pressure when they are lying down. We expect that at the beginning of plasma exchanges, the blood pressure will be relatively high, and the plasma exchanges may be started with the patient in a sitting position. The Principal Investigator or one of the other Associate Investigators of the Clinical Neurocardiology Section will monitor the blood pressure frequently or continuously during the plasma exchanges. Patients with autonomic failure often tolerate remarkably low blood pressure. A systolic blood pressure of 90 mm Hg will be the threshold for intervening. The first intervention will be to place the patient in a supine position. Second, we would administer saline and albumin and slow down the rate of or stop the plasma exchange. Drugs to control blood pressure will also be on hand for immediate emergency use if needed. If we think that we cannot prevent low blood pressure and fainting during future plasma exchanges, then we would exclude the patient from further plasma exchanges under this Protocol. If uncontrollable hypotension occurs in a second patient, then the Protocol will be terminated. Patients are tested for hepatitis and for HIV before undergoing plasma exchange. Blood from people with hepatitis or HIV can contaminate the Blood Bank equipment. If a subject has hepatitis or HIV, the subject will be excluded from further participation in the study. The Consent Form includes standard consent language about HIV testing. Age - The Protocol is restricted to subjects at least 18 years old. Medications - Medications likely to interfere with the scientific results will be discontinued on an inpatient basis. Termination of Participation - A subject may refuse certain tests or procedures, or may terminate participation early, without loss of benefits to which the subject was previously entitled. The Investigators may also exclude a subject from further participation, such as in the event of known or suspect falsification of medical history information or refusal to undergo planned tests or procedures, without loss of benefits to which the subject was previously entitled. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Neurological Disorders and Stroke (NINDS) |
United States,
Goldstein DS, Holmes C, Dendi R, Li ST, Brentzel S, Vernino S. Pandysautonomia associated with impaired ganglionic neurotransmission and circulating antibody to the neuronal nicotinic receptor. Clin Auton Res. 2002 Aug;12(4):281-5. — View Citation
Schroeder C, Vernino S, Birkenfeld AL, Tank J, Heusser K, Lipp A, Benter T, Lindschau C, Kettritz R, Luft FC, Jordan J. Plasma exchange for primary autoimmune autonomic failure. N Engl J Med. 2005 Oct 13;353(15):1585-90. — View Citation
Ziegler MG, Lake CR, Kopin IJ. The sympathetic-nervous-system defect in primary orthostatic hypotension. N Engl J Med. 1977 Feb 10;296(6):293-7. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03593512 -
Deep Brain Stimulation for Autonomic and Gait Symptoms in Multiple System Atrophy
|
N/A | |
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Recruiting |
NCT03312556 -
Treatment of Supine Hypertension in Autonomic Failure (CPAP)
|
N/A | |
Recruiting |
NCT02897063 -
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
|
Phase 1 | |
Completed |
NCT01223391 -
Abdominal Compression in Orthostatic Hypotension
|
N/A | |
Recruiting |
NCT04620382 -
Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
|
Early Phase 1 | |
Recruiting |
NCT05908760 -
CO2 Rebreathing in nOH: A Proof-of-Concept Pilot Study
|
N/A | |
Completed |
NCT03900000 -
Improved Orthostatic Tolerance = Better Cognitive Function in Parkinson's Disease
|
N/A | |
Active, not recruiting |
NCT00678145 -
Mechanisms of Hypoglycemia Associated Autonomic Failure
|
Phase 2 | |
Completed |
NCT00223691 -
Treatment of Orthostatic Hypotension in Autonomic Failure
|
Phase 1 | |
Recruiting |
NCT03482297 -
Automated Abdominal Binder for Orthostatic Hypotension
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489575 -
CPAP for the Treatment of Supine Hypertension
|
N/A | |
Recruiting |
NCT03042988 -
Overnight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension
|
N/A | |
Recruiting |
NCT04782830 -
Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms
|
N/A | |
Recruiting |
NCT04246437 -
[18F]F-DOPA Imaging in Patients With Autonomic Failure
|
Phase 1 | |
Recruiting |
NCT04502225 -
Effect of Raised Head of the Bed on Lying Blood Pressure in Autonomic Failure
|
N/A | |
Recruiting |
NCT02429557 -
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
|
Phase 1 | |
Completed |
NCT02417415 -
Local Heat Stress in Autonomic Failure Patients With Supine Hypertension
|
N/A | |
Completed |
NCT03681080 -
Concentration and Attentional Deficits in POTS and Other Autonomic Neuropathies
|
N/A |